Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ute Dugan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Anticancer Research|April 1, 2009
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenograftsKenneth Kolinsky, Yu-E Zhang, Ute Dugan, et al.
Breast Disease|June 4, 2010
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modelingTiffany A Traina, Ute Dugan, Brian Higgins, et al.
Anticancer Research|August 19, 2007
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft modelBrian Higgins, Kenneth Kolinsky, Michael Linn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancerTiffany A Traina, Maria Theodoulou, Kimberly Feigin, et al.
Molecular Cancer Therapeutics|January 14, 2009
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft modelsKenneth Kolinsky, Ben-Quan Shen, Yu-E Zhang, et al.
JCO Global Oncology|June 8, 2023
Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and OpportunitiesLynne Davies, Danny A Milner, Lawrence N Shulman, et al.
JCO Global Oncology|January 25, 2021
Multisector Collaborations and Global Oncology: The Only Way ForwardCharmaine Blanchard, Buhle Lubuzo, Frederick Chite Asirwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinomaEileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Anticancer Research|April 1, 2009
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenograftsKenneth Kolinsky, Yu-E Zhang, Ute Dugan, et al.
Breast Disease|June 4, 2010
Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modelingTiffany A Traina, Ute Dugan, Brian Higgins, et al.
Anticancer Research|August 19, 2007
Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft modelBrian Higgins, Kenneth Kolinsky, Michael Linn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2008
Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancerTiffany A Traina, Maria Theodoulou, Kimberly Feigin, et al.
Molecular Cancer Therapeutics|January 14, 2009
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft modelsKenneth Kolinsky, Ben-Quan Shen, Yu-E Zhang, et al.
JCO Global Oncology|June 8, 2023
Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and OpportunitiesLynne Davies, Danny A Milner, Lawrence N Shulman, et al.
JCO Global Oncology|January 25, 2021
Multisector Collaborations and Global Oncology: The Only Way ForwardCharmaine Blanchard, Buhle Lubuzo, Frederick Chite Asirwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate CancerMatthew D Galsky, Karen A Autio, Christopher R Cabanski, et al.
Journal for Immunotherapy of Cancer|January 30, 2026
Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinomaEileen M O'Reilly, Christopher R Cabanski, Jaclyn P Lyman, et al.
The Lancet. Oncology|January 2, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b studyMark H O'Hara, Eileen M O'Reilly, Gauri Varadhachary, et al.
Pageof 2